Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

(NasdaqGM:KROS), LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ss”) family of proteins, today announced that Keros' Chair […]

Global Uranium and Forum Energy Metals Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

(CNSX:GURN.CN),(OTC US:GURFF),(Other OTC:GURFF),(Boerse Frankfurt – Freiverkehr:Q3J.F),(Boerse Frankfurt – Freiverkehr:Q3J), CALGARY, Alberta, Jan. 30, 2025 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the “Company“) and Forum Energy Metals Corp. (TSX.V: FMC; OTCQB: FDCFF) (“Forum“) are pleased to announce the completion of data compilation and reprocessing of historical electromagnetic (EM)

ZimVie Announces Publication of a Study Supporting the Benefits of Its Implant Surface Technologies

(NASDAQ:ZIMV), PALM BEACH GARDENS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) — ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced the publication of a detailed scientific study demonstrating the surface texture of ZimVie's premium implants may help to lower the risk of peri-implant infections when compared to other

Veriff Boosts Growth for Startups and SMBs with Streamlined Identity Verification via Zapier

New York, Jan. 30, 2025 (GLOBE NEWSWIRE) — Veriff, a global identity verification and authentication platform, today launched its App for Zapier, empowering businesses to automate verification workflows and accelerate their journey to market. The integration is best suited for small and medium businesses (SMBs) starting their IDV journey with Veriff or looking to streamline

Alpha Modus CEO Addresses Market Volatility and its Recent SPAC Merger

(NasdaqGM:AMOD),(NasdaqGM:AMODW), CORNELIUS, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus”, “AMOD”, or the “Company”), in a statement today, through Alpha Modus CEO William Alessi, emphasized the company's strong fundamentals, ongoing growth strategy, and commitment to delivering value to shareholders amidst what he described as “uninformed speculation” by certain

The RoyaLand Company Ltd. Introduces a New Mobile Companion App for TheRoyal.Land

(Other OTC:RLNDF),(OTC US:RLNDF), Hamilton, Bermuda and Paris, France, Jan. 30, 2025 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (OTCQB: RLNDF) (“RoyaLand” or the “Company”), a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land, today announced the introduction of a mobile companion application for TheRoyal.Land. RoyaLand's companion app

Indicium Launches Unity Catalog Migration Solution for Databricks Customers

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) — Indicium, a global data services consultancy, announces the Unity Catalog Migration, a new solution enabling unified governance of data and AI assets within Databricks, simplifying access, compliance and management across an organization. Large enterprises face fragmented data governance and compliance risks, and inefficiencies in metadata management, often

Reviva to Participate in the 2025 BIO CEO & Investor Conference

(NASDAQ:RVPH),(NASDAQ:RVPH), CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

(NasdaqGM:ALLR), Boston (January 30, 2025)–Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, has filed a Form 8-K with the U.S. Securities and Exchange Commission (“SEC”) regarding its agreement in principle with the SEC staff to

Pyxis Tankers Announces Completion of Common Share Repurchase Program & Update on Chartering Activity

(NASDAQ:PXS), Maroussi, Greece – January 30, 2025 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (“we”, “our”, “us”, the “Company” or “Pyxis Tankers”), an international shipping company, announced today key shareholder and chartering updates. The Company has completed its authorized expanded $3.0 million common share repurchase program. Since summer 2023, we have acquired 730,683 common

Scroll to Top